The FDA has granted fast track status to 67Cu-SAR-bisPSMA for metastatic prostate cancer that is resistant to hormone therapy ...
Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback